Transcranial Direct Current Stimulation (tDCS) for Post COVID-19 Fatigue
Transcranial Direct Current Stimulation (tDCS) for the Treatment of Fatigue in Post-COVID-19 Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Thorsten Rudroff, PHD
- Phone Number: 3194670363
- Email: thorsten-rudroff@uiowa.edu
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Department of Health and Human Physiology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Only those that are discharged from the UIHC COVID-19 inpatient clinic and/or that meet the CDC guidelines for discontinuing home isolation (i.e., fever free for at least 24 hours, all symptoms improved after 10 days) will initially be considered as long as they meet the rest of the following criteria:
Inclusion criteria
- 18-80 yrs.
- Meet CDC guidelines (https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html) for discontinuation of home isolation
- Meet the criteria for fatigue, based on the Chalder Fatigue Scale CFQ-11 case definition of fatigue
- Healthy enough to complete the protocol based, on information obtained from a clinical exam and past medical history, such as cardiovascular disease.
- Comprehension of the protocol, as indicated by an ability to respond to questions about the study after reading the consent form.
- Able to use and be contacted by telephone
- Able to speak, read, and understand English, and complete questionnaires in English
Exclusion criteria
- Medical diagnosis or condition that is considered to be an absolute or relative contraindication to participating in exercise training, such as major renal, pulmonary, hepatic, cardiac, gastrointestinal, HIV, cancer (other than treated basal cell cancer), or neurological disorders
- History/presence of secondary conditions such as seizure disorders (or on medications known to lower seizure threshold), hydrocephalus, diabetes mellitus, or claustrophobia
- Alcohol dependence or abuse (>2 drinks/day), or present history of drug abuse (last six months)
- History of significant traumatic brain injury or hydrocephalus
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: tDCS and fatigue
This group will receive the active form of tDCS.
|
Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation.
It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
Other Names:
|
|
Sham Comparator: Sham and fatigue
This group will receive the sham form of tDCS.
|
Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation.
It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
Other Names:
|
|
Active Comparator: tDCS and non-fatigue
This group will receive the active form of tDCS.
|
Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation.
It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
Other Names:
|
|
Sham Comparator: Sham and non-fatigue
This group will receive the sham form of tDCS.
|
Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation.
It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue Assessment Scale (FAS)
Time Frame: through study completion, an average of 8 weeks
|
Fatigue Questionnaire (1 to 5-point scale x 10 questions for a total score range of 0 to 50) where a low value indicates less fatigued (better outcome) and a high value indicates more fatigued (worse outcome)
|
through study completion, an average of 8 weeks
|
|
Fatigue Severity Scale (FSS)
Time Frame: through study completion, an average of 8 weeks
|
Fatigue Questionnaire (1 to 7 point scale x 9 questions for a total score range of 0 to 63) with a low value indicating less severe fatigue (better outcome) and a high value indicating more severe fatigue (worse outcome)
|
through study completion, an average of 8 weeks
|
|
6-minute Walk Test
Time Frame: through study completion, an average of 8 weeks
|
Distance in meters will be measured in six minutes
|
through study completion, an average of 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 202009381
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.